Niaogan Prescription protects bladder epithelial cells against uropathogenic Escherichia coli invasion / 中草药

ABSTRACT

Objective To observe the role of Niaogan Prescription against uropathogenic Escheriehia coli (UPEC) in invading bladder epithelial cells, and to discuss its mechanism of action. Methods After HTB-9 infected with UPEC, the cell invasion model was used to observe the protective effects of drug urine in human bladder cancer cell 5637 (HTB-9) against UPEC invasion. Effects of Niaogan Prescription on the main steps of signaling pathway Toll-like receptor 4 (TLR4), adenylate cyclase 3 (AC3), cyclic adenosine monophosphate (cAMP), protein kinase A (PKA), and Rac-1 was investigated by molecular biology techniques. Results Compared with the blank urine high dose group (10% volume fraction of blank urine), treatment with the drug-containing urine high dose group of Niaogan Prescription (10% volume fraction of drug urine) resulted in a significant decrease in UPEC invasion, the bacterial invasion rate of the rat blank urine group had no significant difference compared with the model group. Compared with the blank urine high dose group, the drug-containing urine high dose group of Niaogan Prescription improved TLR4 and AC3 protein expression, increased intracellular cAMP content, promoted PKA activation, and inhibited Rac1 activity. Conclusion Niaogan Prescription have the certain capacity against UPEC invasion of bladder epithelial cells, which mechanism is related to TLR4/cAMP signaling pathway. Niaogan Prescription; uropathogenic Escheriehia coli; invasion; human bladder epithelial cells; TLR4/cAMP signal pathway